Anna Bersano, MD, PhD, IRCCS Carlo Besta Neurological Institute Foundation, Milan, Italy, discusses the current limitations and challenges in treating cerebrovascular disorders, particularly in conditions like Fabry disease and CADASIL. While treatments exist for Fabry disease, their efficacy in preventing cerebrovascular complications remains uncertain due to the short duration of follow-ups and the late manifestation of cerebrovascular symptoms. Moreover, most studies have not focused on the neurological aspects of Fabry disease. For conditions like CADASIL, emerging therapies are primarily in the early stages of in vitro and in vivo studies, with human trials yet to commence. The potential role of aspirin in CADASIL management is touched upon, but its efficacy remains unestablished, highlighting the need for comprehensive patient registries to facilitate large-scale studies. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.